Find clear, factual information about our weight loss treatment and any prescription-only medicines that may be prescribed after a GP consultation.

Treatment pathway explained
Every stage is documented and reviewed by a clinician before any prescription is issued or continued.

The two medicines we prescribe
Your GP will discuss which medication is clinically appropriate (if either) for you based on your medical history, eligibility, and response. The two medicines summarised below may be prescribed at the GP's discretion.
The table below shows the current monthly cost of each dose. The starting dose is the lowest, and doses are usually increased every 4 to 8 weeks if treatment is well tolerated and a GP considers it appropriate to continue. One month’s supply consists of four weekly injections, and the monthly cost may change as the dose is adjusted.
| Dose | Price | |
|---|---|---|
| 2.5mg | £98.98 | |
| 0.5mg | £118.97 | |
| 1mg | £148.97 | |
| 1.7mg | £178.97 | |
| 2.4mg | £198.97 |
The table below shows the current monthly cost of each dose. The starting dose is the lowest, and doses are usually increased every 4 to 8 weeks if treatment is well tolerated and a GP considers it appropriate to continue. One month’s supply consists of four weekly injections, and the monthly cost may change as the dose is adjusted.
| Dose | Price | |
|---|---|---|
| 2.5mg | £168.97 | |
| 5mg | £188.97 | |
| 7.5mg | £248.97 | |
| 10mg | £278.97 | |
| 12.5mg | £288.97 | |
| 15mg | £298.97 |
18 years or older. Treatment is not prescribed under 18. Caution is applied for patients over 75.
BMI of 30 kg/m² or more, or BMI of 27 kg/m² or more with at least one weight-related condition (for example hypertension, dyslipidaemia, obstructive sleep apnoea, prediabetes or Type 2 diabetes, PCOS, GORD, NAFLD, osteoarthritis). Ethnicity-adjusted thresholds apply for higher-risk groups.
Treatment is not prescribed in any of the following: • Pregnancy, planning pregnancy, or breastfeeding • Type 1 diabetes • Current use of insulin or sulfonylureas • Active use of another weight loss medication • Known allergy to the medication or its components • End-stage renal disease or dialysis • Active eating disorder • Severe unstable psychiatric illness • Active inflammatory bowel disease • Severe gastrointestinal disease or gastroparesis • Personal or family history of medullary thyroid cancer (Mounjaro) • MEN2 syndrome (Mounjaro) • Severe unstable retinopathy (Wegovy)
If you feel fully informed, book a consultation to discuss suitability and next steps with one of our GPs.